关键词:

肝细胞癌, 醛酮还原酶家族1成员B10, 微血管浸润, 包膜侵犯

Abstract:

Objective　To investigate the expressions of aldo–keto reductase family 1 member B10 (AKR1B10) mRNA and protein in cancer tissues of patients with hepatocellular carcinoma (HCC) and its clinical significance. Methods　Between June 2021 and June 2023, 102 patients with HCC were selected as the study objects, including 55 males and 47 females. They were (56.9±6.4) years old. Among the 102 patients, there were 44 cases with single lesions and 58 cases with multiple lesions. There were 45 cases of TNM stage Ⅰ, 40 cases of TNM stage Ⅱ, and 17 cases of TNM stage Ⅲ. Forty-one cases had microvascular infiltration (MVI), and the rest 61 cases had no MVI. The expression levels of AKR1B10 mRNA in the HCC and adjacent tissues were compared. According to the pathological features, such as tumor maximum diameter, number of lesions, capsule invasion or not, histological differentiation, MVI status, and lymphatic metastasis, the patients were divided into different subgroups. The expressions of AKR1B10 mRNA and protein were compared between the subgroups. The expressions of AKR1B10 mRNA and protein were compared between the patients with different living conditions. t and χ² tests were used for the statistical analysis. Results　The AKR1B10 mRNA in the HCC tissue was higher than that in adjacent tissue (1.5±0.3 vs. 1.0±0.2; t=5.114; P=0.012). The levels of AKR1B10 mRNA in the patients with tumor maximum diameter ≥ 3 cm, capsule invasion, moderate-low histological differentiation, MVI, and lymphatic metastasis were higher than those in the patients with tumor maximum diameter < 3 cm, no capsule invasion, well differentiation, no MVI, and no lymphatic metastasis, with statistical differences (t=4.551, 4.768, -6.197, 4.183, and 7.844; all P<0.05). Among the 102 patients, 73 cases (71.6%) had high expression of AKR1B10 protein. The positive rates of AKR1B10 protein high expression in the patients with capsule invasion, low and moderate tumor differentiation, MVI, and lymphatic metastasis were higher than those in the patients with no capsule invasion, high differentiation, no MVI, and no lymphatic metastasis, with statistical differences (χ²=5.277, -4.184, 8.882, and 11.998; all P<0.05). The patients were followed up one year; among the 102 patients, 69 cases (67.6%) survived, and 33 cases (32.4%) died. The AKR1B10 mRNA level in the cancer tissue in the survived patients was lower than that in the dead patients (1.3±0.3 vs. 1.7±0.4), with a statistical difference (t=4.568,P=0.032). The positive rates of AKR1B10 protein high-expression in the survived and dead patients were 62.3% (43/69) and 90.9% (30/33), respectively, with a statistical significance (χ²=8.968; P=0.003). Conclusion　The high expression of AKR1B10 mRNA and protein in cancer tissue of HCC patients may be related to the malignant degree of tumor cells, and affect the patients' prognosis.

Key words:

Hepatocellular carcinoma, Aldo-keto reductase family 1 member B10, Microvascular infiltration, Capsule invasion